January 9, 2024Scientific ReportsOpen Access

Shikonin alleviates doxorubicin-induced cardiotoxicity via Mst1/Nrf2 pathway in mice

View Full Paper

Ask AI

Bookmark

Why the study?

Doxorubicin cardiotoxicity limits its clinical application, and the study investigated whether shikonin could alleviate DOX-induced cardiac injury and through what mechanisms.

Population

Mice receiving doxorubicin

Comparison

Shikonin vs control in doxorubicin-administered mice

Design

Animal experimental study

Authors

THTuo HuNebraska Medical Center WLWenjing LiUniversity of Science and Technology of China WZWei ZhaoQingdao University

Discussion

Member takes

Implication

Preclinical findings in mice are hypothesis-generating; clinical translation for DOX cardioprotection remains untested.

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hu et al. (2024) studied this question.

synapsesocial.com/papers/6a76e01033def31403ae00a0 https://doi.org/10.1038/s41598-024-51675-7

View Full Paper

Ask AI

Bookmark

Shikonin alleviates doxorubicin-induced cardiotoxicity via Mst1/Nrf2 pathway in mice

Discussion

Member takes

Implication

Key Points

Cite This Study

Shikonin alleviates doxorubicin-induced cardiotoxicity via Mst1/Nrf2 pathway in mice

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider